Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid Checkpoint & Immuno-Oncology Development.
CD200R1 Molecular Characteristics
CD200R1 (CD200 Receptor 1, UniProt Q8TD46) is a myeloid checkpoint receptor with a single Ig-like C2-type domain in its extracellular region. Key known mutations include dbSNP:rs2171509, rs4596117, and rs9826308. The receptor is expressed on monocytes, macrophages, and microglia, and binds to CD200 to transmit inhibitory signals that sustain immune tolerance in the tumor microenvironment.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD200R1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD200R1 ECD-Fc Fusion Protein (Human/Cyno/Mouse orthologs). HEK293 expressed, native glycosylation, >95% purity, Endotoxin <1 EU/µg. Sequence Verified. | View CD200R1 Products |
| Gene Delivery | CD200R1 Promise-ORF / Lentivirus Premade Particles. Full-length ORF with Puromycin selection, for stable cell line generation in functional assays. | View CD200R1 Products |
| Benchmark Antibody | Anti-CD200R1 Antagonist Reference mAb / Biosimilar. Recombinant positive control for blocking and binding assays. | View CD200R1 Products |
| Validator | CD200R1 siRNA Set. Gene-specific knockdown for antibody specificity confirmation. | View CD200R1 Products |
| Ligand Control | CD200 (OX-2) ECD-Fc Protein. Natural ligand for blocking/competition assays; high purity (>95%). | View CD200 Products |
| Selectivity Panel | CD200R1L (CD200R-like) Protein. Off-target counter-screening for subfamily selectivity validation. | View CD200R1L Products |
| Pathway Partner A | CD47. Parallel myeloid checkpoint target; synergistic combination candidate in immuno-oncology. | View CD47 Products |
| Pathway Partner B | SIRP1A. Complementary "don't eat me" signal axis for macrophage reprogramming studies. | View SIRP1A Products |
| Pathway Partner C | PDCD1 (PD-1). Synergistic checkpoint pathway for combination therapies. | View PDCD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ligand Blockade Validation | HEK293-expressed (native glycosylation) ECD-Fc ensures accurate ligand-receptor binding kinetics. |
| Cross-Species Preclinical Evaluation | Human, Cynomolgus, and Mouse ortholog proteins available with identical expression systems and >95% purity. |
| Subfamily Selectivity Screening (CD200R1L vs CD200R1) | CD200R1L counter-screen protein with sequence-verified extracellular domain to rule out off-target binding. |
| Functional Blocking Validation (Cell-based) | Lentivirus-encoded full-length CD200R1 for stable reporter cell lines preserving native conformation and signaling. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies included with guaranteed theoretical MW and high purity (>95%). |
| False Positives in Cell Assays | Validated siRNA included for specificity checks and background noise reduction. |
Live CD200R1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD200R1 therapeutics represents a strategic pivot in immuno-oncology toward myeloid checkpoint modulation. As inhibition of T-cell checkpoints reaches saturation, drug developers are targeting the CD200-CD200R1 axis to reprogram tumor-associated macrophages and myeloid-derived suppressor cells. Early development focused on targeting the ligand CD200 (e.g., Samalizumab) but encountered an "antigen sink" effect due to soluble CD200. The field is now shifting to direct receptor blockade using antagonist monoclonal antibodies. First-generation candidates are completing Phase I safety evaluations, and the next wave of R&D is exploring bispecific formats combining CD200R1 blockade with T-cell engagers or tumor-targeting modalities, alongside rational combinations with CD47/SIRPα inhibitors to maximize macrophage phagocytic activity. Combination with PD-1/PD-L1 inhibitors is also a key synergistic strategy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antagonist mAb | AstraZeneca, Eli Lilly, early-stage biopharma | Solid Tumors, AML, Melanoma | Blocking assay using high-purity CD200R1 ECD-Fc + CD200 Ligand |
| Bispecific / Multi-specific | Preclinical innovators, emerging biotechs | Refractory malignancies, hematologic cancers | Heterodimer validation; co-expression cell lines via lentivirus (CD200R1 + TAA) |
| Combination Therapy | Academic consortia, large pharma | Immunotherapy-refractory tumors | Multiplex selectivity panel (CD200R1 vs CD200R1L) and reporter assays |
| Fusion Protein / Trap | Preclinical-stage developers | Autoimmune diseases | Affinity ranking by SPR; stable receptor format assessment |
| Agonist mAb | Autoimmune specialists | Asthma, rheumatoid arthritis, multiple sclerosis | Signaling assays using lentivirus-generated stable cell lines |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors
- Affinity: Sub-nanomolar Kd required to compete with endogenous CD200; excessively high affinity may cause binding site barrier. Optimal window needed.
- Mechanism: Pure antagonism is mandatory. Any ITIM-like motif phosphorylation would exacerbate immunosuppression.
- Safety: High specificity against CD200R family homologs (CD200R1L, CD200R2); effector-silent Fc (LALA, YTE) to avoid ADCC/CDC depletion of immune cells.
- Cross-species reactivity: Human, cynomolgus, and mouse ortholog cross-reactivity enables seamless IND-enabling toxicology.
Recommended Screening Assays
- Ligand Blockade Assay: SPR/BLI with CD200R1 ECD-Fc vs CD200-Fc.
- Selectivity Panel: Flow cytometry or ELISA against CD200R1L and other family members.
- Functional Cell Assay: Reporter gene or phospho-flow using full-length CD200R1 cell line (lentivirus-generated) to confirm antagonism.
- pH-dependent Binding: For pH-sensitive antibodies targeting acidic tumor microenvironment.
- High-concentration Stability: Accelerated stability at 150 mg/mL using high-purity ECD-Fc to rule out aggregation.
TarMart Solution Design
- ECD-Fc Fusion Protein: HEK293-expressed native glycosylation ensures correct conformation for high-affinity binding and blocking assays.
- Lentivirus Stable Cell Lines: Provide membrane topology and signal transduction capability for functional validation.
- Multi-species Ortholog Coverage: Human, cyno, mouse proteins available for cross-species studies.
- Quality Control: Endotoxin <1 EU/µg, >95% purity, sequence verified.
Related Targets for Cross-Selling
Based on pathway synergy and resistance mechanisms, the following targets are recommended for bundled offerings:
- CD200 (View CD200 Products) – Natural ligand, essential for blocking assays and biomarker detection.
- CD47 (View CD47 Products) – Parallel myeloid checkpoint, synergistic with CD200R1 blockade in macrophage reprogramming.
- SIRP1A (View SIRP1A Products) – Complementary "don't eat me" axis for combination therapy development.
- PDCD1 (View PDCD1 Products) – Key T-cell checkpoint for combination with CD200R1 antagonists.
- HAVCR2 (TIM-3, View HAVCR2 Products) – Another myeloid/lymphoid co-expressed checkpoint for multi-specifics.
- CSF1R (View CSF1R Products) – Regulator of tumor-associated macrophages; complementary to CD200R1 blockade.